Omeros | OMER - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Adma Biologics USD 26.74M 5K 2026-06
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Cytokinetics USD 113.14M 8.75M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Immunic USD 3.45M 451K 2025-12
Insmed USD 253.03M 5.56M 2026-09
Knight Therapeutics CAD 35.45M 4.43M 2025-12
MacroGenics USD 7.9M 1.81M 2026-06
Omeros USD 11.32M 2.48M 2024-09
Pacira USD 950.8M 858.99M 2026-09
Pfizer USD 3.28B 132M 2026-09
Rockwell Medical USD 4.04M 330K 2024-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
United Therapeutics USD 184.1M 22.6M 2026-09
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09